News Article

Candesic had the pleasure of hosting a business dinner at Clearwater Hudson in New York City, led by Aldous Mitchell (Partner) and Blake Edwards (Engagement Manager). The evening brought together a diverse and insightful group of venture capitalists, anaesthesiologists, psychiatrists, and private equity investors to explore the evolving landscape of psychedelic-based therapies in the U.S.

Our roundtable discussion covered a range of fascinating topics, including:
– Innovative approaches to modelling dopamine and serotonin expression to better understand brain function
– Insights into iboga its potential role in reducing opioid tolerance and supporting detoxification
– Advances in mapping organised neural cell networks to study the effects of compounds in a controlled, in-vivo-like environment

We also explored the current position of psychedelics as a niche and somewhat fringe component of the broader treatment paradigm—while recognising the growing body of evidence and interest supporting their clinical potential. The group discussed long-term pathways for commercialisation, from trial design and safety protocols to reimbursement models and investor confidence in building scalable treatment frameworks.

It was an engaging and thought-provoking evening, and we’re grateful to those who contributed their perspectives. We look forward to continuing the conversation at future events.